New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
07:39 EDTHZNPHorizon Pharma announces Notice of Allowance from USPTO covering Rayos
Horizon Pharma announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office, or USPTO, for U.S. Patent Application 13/428,548 entitled "Delayed Release Tablet with Defined Core Geometry" that covers the company's U.S. approved product Rayos. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2024. After issuance, Horizon plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the third U.S. patent to be listed in the Orange Book for Rayos.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
07:45 EDTHZNPHorizon Pharma to host conference call
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma acquires U.S. rights to PENNSAID 2% for $45M
Subscribe for More Information
October 13, 2014
17:06 EDTHZNPHorizon Pharma: Actimmune net sales potential $500M with FDA approval for FA
Subscribe for More Information
05:31 EDTHZNPHorizon Pharma to host analyst day
Analyst Day to be held in King of Prussia, PA on October 13 at 5 pm. Webcast Link
October 9, 2014
15:31 EDTHZNPHorizon Pharma's Actimmune Phase 2 results provide more growth, says Avondale
Avondale said Horizon Pharma's Actimmune Phase 2 results were strong and support incremental annual market opportunity of approximately $300K per year. The firm views the results as another potential growth driver and its Outperform rating and $22 price target.
13:40 EDTHZNPHorizon Pharma presents ACTIMMUNE Phase 2 data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use